Annovis Bio (NYSE: ANVS) plans to deliver three presentations at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, scheduled for Nov. 16-19, 2026, in Boston, the company announced. The presentations will focus on its investigational oral therapy buntanetap, covering its mechanism of action, the design and baseline characteristics of its pivotal Phase 3 study in early Alzheimer's disease, and the use of artificial intelligence to predict blood-brain barrier permeability of late-stage Alzheimer's drug candidates.
The conference program includes an oral presentation on Nov. 19 by Alexander Morin, director of strategic communications, and two poster presentations on Nov. 16-17, one of which will be delivered by Chief Scientific Officer Cheng Fang. According to Annovis, the presentations reflect progress in the buntanetap development program as the company approaches a pivotal clinical data readout in early 2027 and prepares for a New Drug Application.
The timing matters for investors and patients alike. A pivotal readout is the decisive test of whether an experimental therapy can support regulatory approval, and Annovis is signaling that its Phase 3 trial in early Alzheimer's disease is far enough along to detail its design and baseline characteristics publicly. For a Phase 3 clinical-stage biotechnology company, such disclosures can shape expectations well before the data arrive.
Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The company, headquartered in Malvern, Pennsylvania, is developing treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. More information is available at www.annovisbio.com.
The AI element of the CTAD program also carries weight beyond this single trial. Blood-brain barrier permeability is a longstanding hurdle in neuroscience drug development, because a compound that cannot cross into the brain cannot act on its targets there. A validated AI approach for predicting permeability could help prioritize late-stage Alzheimer's candidates and reduce costly failures, which is why the methodology may draw attention from researchers and rival developers.
The full press release is available at https://nnw.fm/2k4SQ, and the latest news and updates relating to ANVS are available in the company's newsroom at https://nnw.fm/ANVS. The announcement was distributed through NetworkNewsWire, part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. Terms of use and disclaimers are posted at https://www.NetworkNewsWire.com/Disclaimer.
